Relay Therapeutics Inc [RLAY] stock prices are down -2.48% to $6.29 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RLAY shares have gain 3.97% over the last week, with a monthly amount drifted -3.38%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Equal Weight rating on April 17, 2025, and set its price target to $4. On September 10, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $16 on the stock. Oppenheimer downgraded its rating to a Perform. Barclays upgraded its rating to Overweight for this stock on May 10, 2024, but kept the price target unchanged to $15. In a note dated April 20, 2023, Jefferies upgraded an Hold rating on this stock but restated the target price of $12.50.
The stock price of Relay Therapeutics Inc [RLAY] has been fluctuating between $1.77 and $7.64 over the past year. Currently, Wall Street analysts expect the stock to reach $19.4 within the next 12 months. Relay Therapeutics Inc [NASDAQ: RLAY] shares were valued at $6.29 at the most recent close of the market. An investor can expect a potential return of 208.43% based on the average RLAY price forecast.
Analyzing the RLAY fundamentals
Gross Profit Margin for this corporation currently stands at 0.13% with Operating Profit Margin at -39.14%, Pretax Profit Margin comes in at -35.61%, and Net Profit Margin reading is -35.61%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.43 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.10 points at the first support level, and at 5.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.60, and for the 2nd resistance point, it is at 6.91.
Ratios To Look Out For
It’s worth pointing out that Relay Therapeutics Inc [NASDAQ:RLAY]’s Current Ratio is 19.14. Also, the Quick Ratio is 19.14, while the Cash Ratio stands at 2.81. Considering the valuation of this stock, the price to sales ratio is 130.41, the price to book ratio is 1.79.
Transactions by insiders
Recent insider trading involved Patel Sanjiv, President and CEO, that happened on Nov 03 ’25 when 62073.0 shares were sold. Rahmer Peter completed a deal on Oct 29 ’25 to sell 21394.0 shares. Meanwhile, Rahmer Peter sold 19135.0 shares on Oct 28 ’25.
